FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151694080> ?p ?o ?g. }

• W2151694080 endingPage "1171" @default.
• W2151694080 startingPage "1164" @default.
• W2151694080 abstract "Purpose To determine whether autologous (auto) or allogeneic (allo) stem-cell transplantation (SCT) improves outcome in patients with transformed follicular lymphoma compared with rituximab-containing chemotherapy alone. Patients and Methods This was a multicenter cohort study of patients with follicular lymphoma and subsequent biopsy-proven aggressive histology transformation. Patient, treatment, and outcome data were collected from each transplantation center and combined for analysis. A separate control group was composed of patients with transformation treated with rituximab-containing chemotherapy but not SCT. The primary end point was overall survival (OS) after transformation. Results One hundred seventy-two patients were identified: 22 (13%) treated with alloSCT, 97 (56%) with autoSCT, and 53 (31%) with rituximab-containing chemotherapy. Five-year OS after transformation was 46% for patients treated with alloSCT, 65% with autoSCT, and 61% with rituximab-containing chemotherapy (P = .24). Five-year progression-free survival (PFS) after transformation was 46% for those treated with alloSCT, 55% with autoSCT, and 40% with rituximab-containing chemotherapy (P = .12). In multivariate analysis, patients treated with autoSCT had improved OS compared with those who received rituximab-containing chemotherapy (hazard ratio [HR], 0.13; 95% CI, 0.05 to 0.34; P < .001). On the other hand, there was no OS difference between those treated with alloSCT and rituximab-containing chemotherapy (HR, 0.44; 95% CI, 0.16 to 1.24; P = .12). OS and PFS after SCT were similar between those treated with autoSCT and alloSCT. Five-year transplantation-related mortality was 23% for those treated with alloSCT and 5% for autoSCT. Conclusion Patients undergoing autoSCT had better outcomes than those treated with rituximab-containing chemotherapy alone. AlloSCT did not improve outcome compared with rituximab-containing chemotherapy and was associated with clinically significant toxicity." @default.
• W2151694080 created "2016-06-24" @default.
• W2151694080 creator A5002628051 @default.
• W2151694080 creator A5006267560 @default.
• W2151694080 creator A5008056180 @default.
• W2151694080 creator A5011619265 @default.
• W2151694080 creator A5017873196 @default.
• W2151694080 creator A5020565431 @default.
• W2151694080 creator A5021115725 @default.
• W2151694080 creator A5022658681 @default.
• W2151694080 creator A5027155042 @default.
• W2151694080 creator A5031948436 @default.
• W2151694080 creator A5037547547 @default.
• W2151694080 creator A5040518471 @default.
• W2151694080 creator A5044632878 @default.
• W2151694080 creator A5045731423 @default.
• W2151694080 creator A5048152755 @default.
• W2151694080 creator A5055324220 @default.
• W2151694080 creator A5061538879 @default.
• W2151694080 creator A5061856914 @default.
• W2151694080 creator A5066224233 @default.
• W2151694080 creator A5068947490 @default.
• W2151694080 creator A5070661848 @default.
• W2151694080 creator A5073327231 @default.
• W2151694080 creator A5078589170 @default.
• W2151694080 creator A5083858828 @default.
• W2151694080 date "2013-03-20" @default.
• W2151694080 modified "2023-10-02" @default.
• W2151694080 title "Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group" @default.
• W2151694080 cites W1728781233 @default.
• W2151694080 cites W1777323899 @default.
• W2151694080 cites W1897819006 @default.
• W2151694080 cites W1912693401 @default.
• W2151694080 cites W1964744337 @default.
• W2151694080 cites W1969013721 @default.
• W2151694080 cites W1971899950 @default.
• W2151694080 cites W1977903128 @default.
• W2151694080 cites W1982408296 @default.
• W2151694080 cites W2001302091 @default.
• W2151694080 cites W2019131761 @default.
• W2151694080 cites W2056151406 @default.
• W2151694080 cites W2058015212 @default.
• W2151694080 cites W2081222723 @default.
• W2151694080 cites W2085459287 @default.
• W2151694080 cites W2096242966 @default.
• W2151694080 cites W2101648653 @default.
• W2151694080 cites W2106928992 @default.
• W2151694080 cites W2118826067 @default.
• W2151694080 cites W2127749132 @default.
• W2151694080 cites W2137747969 @default.
• W2151694080 cites W2145745667 @default.
• W2151694080 cites W2153665789 @default.
• W2151694080 cites W2154643481 @default.
• W2151694080 cites W2159982513 @default.
• W2151694080 cites W2160305510 @default.
• W2151694080 cites W2167571754 @default.
• W2151694080 cites W2169578616 @default.
• W2151694080 cites W2239810334 @default.
• W2151694080 cites W2243418522 @default.
• W2151694080 cites W2979885356 @default.
• W2151694080 cites W2980266043 @default.
• W2151694080 cites W4293241248 @default.
• W2151694080 doi "https://doi.org/10.1200/jco.2012.44.0693" @default.
• W2151694080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23401459" @default.
• W2151694080 hasPublicationYear "2013" @default.
• W2151694080 type Work @default.
• W2151694080 sameAs 2151694080 @default.
• W2151694080 citedByCount "85" @default.
• W2151694080 countsByYear W21516940802013 @default.
• W2151694080 countsByYear W21516940802014 @default.
• W2151694080 countsByYear W21516940802015 @default.
• W2151694080 countsByYear W21516940802016 @default.
• W2151694080 countsByYear W21516940802017 @default.
• W2151694080 countsByYear W21516940802018 @default.
• W2151694080 countsByYear W21516940802019 @default.
• W2151694080 countsByYear W21516940802020 @default.
• W2151694080 countsByYear W21516940802021 @default.
• W2151694080 countsByYear W21516940802022 @default.
• W2151694080 countsByYear W21516940802023 @default.
• W2151694080 crossrefType "journal-article" @default.
• W2151694080 hasAuthorship W2151694080A5002628051 @default.
• W2151694080 hasAuthorship W2151694080A5006267560 @default.
• W2151694080 hasAuthorship W2151694080A5008056180 @default.
• W2151694080 hasAuthorship W2151694080A5011619265 @default.
• W2151694080 hasAuthorship W2151694080A5017873196 @default.
• W2151694080 hasAuthorship W2151694080A5020565431 @default.
• W2151694080 hasAuthorship W2151694080A5021115725 @default.
• W2151694080 hasAuthorship W2151694080A5022658681 @default.
• W2151694080 hasAuthorship W2151694080A5027155042 @default.
• W2151694080 hasAuthorship W2151694080A5031948436 @default.
• W2151694080 hasAuthorship W2151694080A5037547547 @default.
• W2151694080 hasAuthorship W2151694080A5040518471 @default.
• W2151694080 hasAuthorship W2151694080A5044632878 @default.
• W2151694080 hasAuthorship W2151694080A5045731423 @default.
• W2151694080 hasAuthorship W2151694080A5048152755 @default.
• W2151694080 hasAuthorship W2151694080A5055324220 @default.
• W2151694080 hasAuthorship W2151694080A5061538879 @default.
• W2151694080 hasAuthorship W2151694080A5061856914 @default.

• next